This article is more than 5 years old. Information may no longer be current.

VIDEO: Siegel discusses IBD severity vs. activity

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ORLANDO — In this video exclusive from AIBD 2016, Corey A. Siegel, MD, MS, of the Dartmouth-Hitchcock Inflammatory Bowel Disease Center in New Hampshire, discussed his presentation on differentiating between disease severity and disease activity.

“The main message from [my] talk was: disease activity is not the same as disease severity,” he said. “We can think about [how patients are] doing today, but we need to think about their overall disease status when we’re thinking about a therapeutic strategy for the future.”

Reference:

Siegel C. “Determination of disease severity.” Presented at: Advances in Inflammatory Bowel Diseases; Dec. 8-10, 2016; Orlando, Fla.

Disclosures: Siegel reports he serves as a consultant and on advisory boards for AbbVie, Amgen, Janssen, Lilly, Pfizer, Prometheus, Salix, Takeda, Theradiag and UCB; has presented CME activities for AbbVie, Janssen and Takeda; and has received grant support from AbbVie, Janssen, Salix, Takeda and UCB.